Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.

ABSTRACT:

Importance

Novel androgen receptor inhibitors (ARIs; darolutamide, enzalutamide, and apalutamide) are standard-of-care treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC). However, there are sparse data comparing their clinical use and tolerability.

Objective

To compare clinical use and outcomes for darolutamide, enzalutamide, and apalutamide in patients with nmCRPC.

Design, setting, and participants

This retrospective cohort study reviewed electronic medical records from the Precision Point Specialty network of US urology practices. Eligible patients had nmCRPC and no prior novel hormonal therapy and initiated novel ARI treatment between August 1, 2019, and March 31, 2022. Data were analyzed from February 1, 2019, to December 31, 2022.

Expos

SUBMITTER: George DJ 

PROVIDER: S-EPMC11350483 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature